Cargando…

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

OBJECTIVE: Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti‐Aβ antibodies are capable of lowering oAβ levels in humans. METHODS: We developed an ultrasensitive immunoassay and used it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Ting, Dang, Yifan, Ostaszewski, Beth, Mengel, David, Steffen, Verena, Rabe, Christina, Bittner, Tobias, Walsh, Dominic M., Selkoe, Dennis J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771589/ https://www.ncbi.nlm.nih.gov/pubmed/31168802 http://dx.doi.org/10.1002/ana.25513

Ejemplares similares

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
por: Yoshida, Kenta, et al.
Publicado: (2020)

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials
por: Ostrowitzki, Susanne, et al.
Publicado: (2022)

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
por: Salloway, Stephen, et al.
Publicado: (2018)

A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2015)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

An Aged Canid with Behavioral Deficits Exhibits Blood and Cerebrospinal Fluid Amyloid Beta Oligomers
por: Rusbridge, Clare, et al.
Publicado: (2018)

Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
por: Kawamura, Kaito, et al.
Publicado: (2021)

How do Soluble Oligomers of Amyloid β-protein Impair Hippocampal Synaptic Plasticity?
por: Li, Shaomin, et al.
Publicado: (2010)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease
por: Li, Shaomin, et al.
Publicado: (2018)

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
por: Cummings, Jeffrey L., et al.
Publicado: (2018)

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
por: Ultsch, Mark, et al.
Publicado: (2016)

Soluble Aβ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region
por: Zhao, Jianhua, et al.
Publicado: (2018)

Secreted Amyloid β-Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity
por: Welzel, Alfred T., et al.
Publicado: (2014)

Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ
por: Meilandt, William J., et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
por: Guthrie, Heather, et al.
Publicado: (2020)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Heteromers of amyloid precursor protein in cerebrospinal fluid
por: Cuchillo-Ibañez, Inmaculada, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
por: Banerjee, Gargi, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy
por: Sembill, Jochen A, et al.
Publicado: (2023)

Conformation-Dependent Oligomers in Cerebrospinal Fluid of Presymptomatic Familial Alzheimer's Disease Mutation Carriers
por: Ringman, John M., et al.
Publicado: (2012)

Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium
por: Xie, Zhongcong, et al.
Publicado: (2014)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Remarkably Efficient Blood–Brain Barrier Crossing Polyfluorene–Chitosan Nanoparticle Selectively Tweaks Amyloid Oligomer in Cerebrospinal Fluid and Aβ1–40
por: Roy Chowdhury, Sayan, et al.
Publicado: (2018)

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
por: Haass, Christian, et al.
Publicado: (2022)

Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals
por: Chhatwal, Jasmeer P., et al.
Publicado: (2020)

The Toxicity of Amyloid β Oligomers
por: Zhao, Li Na, et al.
Publicado: (2012)

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease
por: Park, Min Jeong, et al.
Publicado: (2011)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis
por: Banerjee, Gargi, et al.
Publicado: (2021)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

The amyloid hypothesis of Alzheimer's disease at 25 years
por: Selkoe, Dennis J, et al.
Publicado: (2016)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

A Is for Amyloid
por: Selkoe, D. J.
Publicado: (2020)

Immunogenic properties of amyloid beta oligomers
por: Dalgediene, Indre, et al.
Publicado: (2013)

Breaking the Code of Amyloid-β Oligomers
por: Lesné, Sylvain E.
Publicado: (2013)

The Toxicity and Polymorphism of β-Amyloid Oligomers
por: Huang, Ya-ru, et al.
Publicado: (2020)

Single Molecule Characterization of Amyloid Oligomers
por: Yang, Jie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i4ucv1gcvivvlnktakckpftlih